FDA approves updated prescribing information for Tradjenta (linagliptin) tablets for add-on ...
06:22 EDT 19 Aug 2012 | LaMerie
Updated label also includes data on adult patients with type 2 diabetes who have severe chronic renal impairment, providing further evidence TRADJENTA is an efficacious DPP-4 inhibitor with a demonstrated safety profile
Original Article: FDA approves updated prescribing information for Tradjenta (linagliptin) tablets for add-on ...
More From BioPortfolio on "FDA approves updated prescribing information for Tradjenta (linagliptin) tablets for add-on ..."
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
